Last reviewed · How we verify
nicotine patch, labeled use
The nicotine patch, developed by the University of Vermont, is a transdermal delivery system designed to aid in smoking cessation. It works by releasing a controlled amount of nicotine into the bloodstream, which helps reduce withdrawal symptoms and cravings associated with quitting smoking. Despite its effectiveness, the nicotine patch has not received FDA approval, and its use is primarily off-label. Common side effects include skin irritation at the application site, headache, and dizziness. The patch is generally considered safe but may interact with other medications and is contraindicated in certain populations.
At a glance
| Generic name | nicotine patch, labeled use |
|---|---|
| Also known as | Nicoderm Clear 21 mg, Nicoderm Clear 14 mg, Nicoderm Clear 7 mg |
| Sponsor | University of Vermont |
| Drug class | Nicotine replacement therapy |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Depressed Mood Improvement Through Nicotine Dosing-3 (Depressed MIND3) Extension (PHASE2)
- Optimizing Tobacco Use Treatment for PLWHA (PHASE3)
- PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine. (PHASE4)
- Evaluating Smoking Cessation Interventions for PWH in South Africa (PHASE2, PHASE3)
- Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study (NA)
- WeChat Quit Coach Pilot Study (NA)
- Personalized Dosing of Nicotine Replacement (NRT to Effect) (PHASE4)
- Depressed Mood Improvement Through Nicotine Dosing 2 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nicotine patch, labeled use CI brief — competitive landscape report
- nicotine patch, labeled use updates RSS · CI watch RSS
- University of Vermont portfolio CI